IntelGenx To Present at Biotech Showcase(TM) 2018

SAINT-LAURENT, Quebec, Jan. 04, 2018 -- IntelGenx Corp. (TSX VENTURE:IGX) (OTCQX:IGXT) (the "Company" or "IntelGenx") today announced that its President and Chief Executive Officer, Dr. Horst Zerbe, is scheduled to present an overview of the Company’s business at the 10^th Annual Biotech Showcase™ conference on Tuesday, January 9 at 9:00 a.m. Pacific Time at the Hilton San Francisco Union Square Hotel.

The presentation will be webcast live and archived for 90 days on the Company's website, at www.intelgenx.com, under "Investors".

Andre Godin, Executive Vice President and Chief Financial Officer, and Dr. Dana Matzen, Vice President Business and Corporate Development, from IntelGenx will also be available for one-on-one meetings in San Francisco from January 8 through 10. To arrange an investor meeting with IntelGenx, please contact Stephen Kilmer ([email protected]) and to arrange a business development meeting please contact Dr. Laëtitia Rodes ([email protected]).

About IntelGenx:

Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.

IntelGenx' highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx' state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients.  More information about the company can be found at www.intelgenx.com. 

Forward-Looking Statements:

This document may contain forward-looking information about IntelGenx' operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx' plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx' actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx' annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities and www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.

Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release.

Source: IntelGenx Technologies Corp.

Contacts :

Stephen Kilmer
Investor Relations
(514) 331-7440 ext 232
[email protected]

Andre Godin, CPA, CA
Executive Vice-President and CFO
(514) 331-7440 ext 203
[email protected]